Clinical Trials
36 trialsCUREMZL002
Institute of Hematology & Blood Diseases Hospital, China
Ultra-low-dose Radiation Therapy Followed by Orelabrutinib as First-line Treatment for Stage â… -â…¡ MALT Lymphoma
Zhejiang Cancer Hospital
Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)
Sun Yat-sen University
Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation
The First Affiliated Hospital of Soochow University
MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL
Ruijin Hospital
Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL
The First Affiliated Hospital with Nanjing Medical University
MZL-IIT-O
Institute of Hematology & Blood Diseases Hospital, China
Orelabrutinib Followed by Response-adapted Ultra-low Dose 4Gy Radiation as First-line Treatment of MALT Lymphoma
Fudan University
Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma
Beijing Tongren Hospital
Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease
Ruijin Hospital
Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma
Peking University Third Hospital
Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy
The First Affiliated Hospital with Nanjing Medical University
Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL
The First Affiliated Hospital with Nanjing Medical University
ADAPT-MCL
Tianjin Medical University Cancer Institute and Hospital
Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment
Ruijin Hospital
Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial
The First Affiliated Hospital of Nanchang University
Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL
Affiliated Hospital of Nantong University
A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma
Ruijin Hospital
Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial）
Sun Yat-sen University
Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma
Huai'an First People's Hospital
Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy
The First Affiliated Hospital of Xiamen University
A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL
The First Affiliated Hospital with Nanjing Medical University
Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas
Institute of Hematology & Blood Diseases Hospital, China
Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment
Ruijin Hospital
Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.
Peking Union Medical College Hospital
Orelabrutinib Therapy in Patients With r/r B-cell Lymphoma Intolerant to Other Bruton Tyrosine Kinase Inhibitors
Peking University People's Hospital
An Ambispective Cohort Study of Orelabrutinib in Combination With Standard Treatment Regimen for Untreated DLBCL
The First Affiliated Hospital with Nanjing Medical University
Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients
The First Affiliated Hospital of Soochow University
Genotype-guided Treatment in DLBCL
Ruijin Hospital
Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCL
The First Affiliated Hospital of Soochow University
Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL
The First Affiliated Hospital with Nanjing Medical University
A Study of OLR in First-line Treatment of Mantle Cell Lymphoma
Tianjin Medical University Cancer Institute and Hospital
Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell Lymphoma
Puyang Oilfield General Hospital
Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma
Sun Yat-sen University